Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Pirenzepine |
EINECS | 249-228-4 |
CAS No. | 28797-61-7 | Density | N/A |
PSA | 74.23000 | LogP | 2.80740 |
Solubility |
Stability
Toxicology | ||
Formula | C19H21 N5 O2 | Boiling Point | 541.7°C at 760 mmHg |
Molecular Weight | 351.408 | Flash Point | 281.4°C |
Transport Information | N/A | Appearance | solid |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one,5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- (8CI,9CI); Pirenzepin;Pirenzepine |
Article Data | 5 |
Molecular structure of Pirenzepine (CAS NO.28797-61-7) is:
Product Name: Pirenzepine
CAS Registry Number: 28797-61-7
IUPAC Name: 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
Molecular Weight: 351.40234 [g/mol]
Molecular Formula: C19H21N5O2
XLogP3: 0.1
H-Bond Donor: 1
H-Bond Acceptor: 5
Surface Tension: 53.7 dyne/cm
Density: 1.271 g/cm3
Flash Point: 281.4 °C
Enthalpy of Vaporization: 81.97 kJ/mol
Boiling Point: 541.7 °C at 760 mmHg
Vapour Pressure: 8.44E-12 mmHg at 25°C
Classification Code: Anti-ulcer agents ;Cholinergic Agents ;Cholinergic Antagonists ;Drug / Therapeutic Agent ;Gastrointestinal Agents ;Muscarinic antagonists ;Neurotransmitter Agents
Product Categories: Muscarinic
Pirenzepine (CAS NO.28797-61-7) is an antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as Cimetidine and Ranitidine. It is generally well tolerated by patients. Aslo, it can used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It has no effects on the brain and spinal cord as it cannot diffuse through the blood-brain barrier. And it has been investigated for use in myopia control.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 427mg/kg (427mg/kg) | Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 26, Pg. 245, 1991. | |
mouse | LD50 | intravenous | 156mg/kg (156mg/kg) | Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 26, Pg. 245, 1991. | |
mouse | LD50 | oral | 3046mg/kg (3046mg/kg) | Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 26, Pg. 245, 1991. | |
rat | LD50 | oral | > 5gm/kg (5000mg/kg) | Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 26, Pg. 245, 1991. |
Pirenzepine , its cas register number is 28797-61-7. It also can be called Pirenzepine [INN:BAN] ; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one ; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one ; BRN 0628987 ; EINECS 249-228-4 ; Pirenzepin ; Pirenzepina ; Pirenzepina [INN-Spanish] ; Pirenzepinum ; Pirenzepinum [INN-Latin] ; UNII-3G0285N20N ; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)- .And, it is a solid.